Jason W. Schigelone
Shareholder

Jason focuses his practice on patent litigation and prosecution in the chemical, medical and mechanical arts.  He has experience in domestic and international patent prosecution and patent clearance opinions, and has represented clients through all stages of litigation in the federal district courts and before the Court of Appeals for the Federal Circuit.  Jason has handled matters involving a variety of technologies, including interventional medical devices and healthcare products, pharmaceuticals, biosensors, climate control, and automotive systems.

As a veteran of the automotive industry, Jason brings a client-side perspective to his practice. Jason has been involved in all aspects of the technology life cycle – as a manufacturing and materials engineer involved in product development, as an in-house patent engineer involved in IP development and valuation, and as an attorney involved in prosecuting and litigating patents. These experiences give him real-world perspective and appreciation of the issues that matter most to clients, helping him to achieve efficient and effective solutions.

Jason is known for his thorough and detailed understanding of his client’s technologies and business, and his ability to translate this information into successful legal strategies and outcomes.

Practice Groups
Education
  • J.D.,
    Wayne State University Law School, 2005
  • M.S., Chemical Engineering
    University of Michigan, 2000
  • B.S., Chemical Engineering
    University of Michigan, 1984
Bar Admissions
  • Illinois
  • U.S. Court of Appeals, Fed. Cir.
  • U.S. Dist. Court, N.D. Illinois
  • U.S. Patent & Trademark Office
Technical Background
  • Chemical Engineering
Experience | Overview
  • Jason was elected as counsel for Brinks Gilson & Lione effective in January 2015.
  • Jason has successfully litigated on numerous occasions on behalf of long-time client Cook Incorporated. This includes a recent victory in the U.S. District Court for the Southern District of Indiana involving Cook’s Zenith® endovascular grafts used in treating abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs).  Jason is defending Cook against infringement claims brought by Endotach LLC. The district court granted summary judgment in Cook Medical’s favor, resulting in the dismissal of the case. Endotach appealed to the Federal Circuit of Appeals. The appeal is currently pending.
  • With a decade worth of experience in the automotive industry, Jason brings a strong engineering background, and a unique, real-world perspective to his clients and caseload.
Experience | Legal

Brinks Gilson & Lione, Chicago, Illinois
Counsel, January 2015-Present
Associate, September 2005-December 2014

Visteon Global Technologies Inc., Van Buren Township, Michigan
Patent Engineer, 2003-2005

Brooks Kushman P.C., Southfield, Michigan
Summer Associate, 2004

Experience | Non-Legal

Visteon Corporation, Dearborn, Michigan
Advanced Materials/Manufacturing, 2000-2003

Ford Motor Company, Dearborn, Michigan
Materials Testing and Analysis/Manufacturing/Quality Control, 1994-2000

Forward Thinking
in the media
January 12, 2017
On January 12, 2017, various media outlets published the announcement regarding the newly elected shareholders in 2017.  Please visit here and here and here to read more.
in the media
January 06, 2017
On January 6, 2017, the Chicago Daily Law Bulletin announced that Mark Remus and Jason Schigelone were elected as shareholders in the In the News column. Click here to read more.
alert
May 19, 2016

The Supreme Court recently granted a petition for writ of certiorari to review the Federal Circuit’s en banc decision in SCA Hygiene Prods. Aktiebolag v. First Quality Baby Prods., LLC.

alert
May 12, 2016

President Obama signed into law yesterday the Defend Trade Secrets Act, establishing for the first time an ostensibly uniform national trade secret protection standard...
 

alert
July 21, 2015
The Biologic Price Competition and Innovation Act (“BPCIA”) was enacted in 2010 to provide an abbreviated pathway for FDA approval of biologic products (“biosimilars”) deemed sufficiently similar to products already on the ...
alert
March 09, 2015
Friday marked the FDA’s first-ever approval of a biosimilar application under the Biologics Price Competition and Innovation Act (BPCIA), 42 U.S.C. § 262. The BPCIA was enacted back in 2010 as part of the Patient Protection and ...
in the media
January 14, 2015
Manish Mehta and Jason Schigelone’s new appointments were mentioned in the January 13 issue of Chicago Daily Law Bulletin. Click here to read more.
in the media
October 07, 2014
On October 2, 2014, Jason Schigelone was quoted in IPPro Life Sciences (Issue 29) in an article entitled, “Going it alone: Australia allows isolated gene patents.” Click here to read more.
Presentations
  • "Fee-Shifting Strategies in Patent Cases," Moderator, Centerforce IP Strategy Summit, November 8, 2016
  • "Update on Pending Patent Reform: Evaluating the Continually Evolving Impact of Non-Practicing Entities, Patent Assertion Entities, and Other Monetizers," ACI Medical Device Patents Summit, New York, NY, February 25, 2016
  • "Examining New Rulings in Inducement of Infringement and Divided Infringement and Their Application to Method Claims in Hatch-Waxman Litigation," Panelist, ACI's Paragraph VI Disputes: Expert Insights on Hatch-Waxman Litigation Strategies for Brand Names and Generics, New York City, May 8, 2013
  • "Beyond Coatings: Automotive Flexible Coverskins," Presenter, International Coatings for Plastics Symposium, Spring 2002
Representative Matters
  • LifePort Sciences LLC and LifeScreen Sciences LLC v. Cook Incorporated and Cook Medical Incorporated (D. Del. 2013-present). Mr. Schigelone represents Cook Incorporated and Cook Medical in several patent infringement actions filed by LifePort and LifeScreen concerning endovascular stent graft and vena cava filter technologies.
  • Endotach LLC v. Cook Medical Inc. (S.D. Ind. 2012-present). Mr. Schigelone represents Cook Medical in a patent infringement action filed by Endotach concerning endovascular stent grafts for treating aneurysms.
  • Boston Scientific Corp., Boston Scientific Scimed, Inc., Boston Scientific Ltd., and Endovascular Technologies, Inc. v. Cook Incorporated, Wilson-Cook Medical, Inc., Cook Medical Inc., Cook Ireland Ltd., Taewoong Medical Co., Ltd., Standard Sci-Tech Inc., EndoChoice, Inc., and Sewoon Medical Co., Ltd. (D. Mass. 2010). Mr. Schigelone represents the Cook entities in a patent infringement action concerning stents for treating blockages, such as cancer, in the esophagus.
  • Cook Incorporated v. Endologix, Inc. (S.D. Ind. 2009). Mr. Schigelone represented Cook Incorporated in a patent infringement action concerning endovascular stent grafts for treating abdominal aortic aneurysms.
  • AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals, Inc., Astrazeneca AB, and The Brigham and Women’s Hospital, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2010). Mr. Schigelone represented Teva Pharmaceuticals USA in a second Hatch-Waxman action concerning the cholesterol-lowering drug, Crestor®, and its active ingredient, rosuvastatin calcium.
  • Millennium Pharmaceuticals, Inc. and Schering Corp. v. Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries Ltd. (D. Del. 2009). Mr. Schigelone represented Teva Parenteral Medicines, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries in a Hatch-Waxman patent infringement action concerning the anti-coagulant drug, Integrilin®, and its active ingredient, eptifibatide.
  • AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, IPR Pharmaceuticals Inc., and Shionogi Seiyaku Kabushiki Kaisha v. Teva Pharmaceuticals USA, Inc. (D. Del. 2008-present). Mr. Schigelone represents Teva Pharmaceuticals USA in a Hatch-Waxman action concerning the cholesterol-lowering drug, Crestor®, and its active ingredient, rosuvastatin calcium.
  • Edwards Lifesciences, LLC and EndoGAD Pty, Ltd. v. Cook Incorporated, Medtronic, Inc., Medtronic AVE, Inc., and W.L. Gore & Associates, Inc. (N.D. California 2003-2009). Mr. Schigelone represented Cook Incorporated in a patent infringement action concerning endovascular stent-grafts for treating aneurysms.
Press Releases & Events
October 20, 2016

CHICAGO—Jason Schigelone, a patent attorney at intellectual property law firm Brinks Gilson & Lione, will be a...

February 25, 2016

Brinks is sponsoring ACI's 6th Annual Advanced Summit on Medical Device Patents on taking ...

January 05, 2015
CHICAGO—Brinks Gilson & Lione, one of the nation’s largest intellectual property law firms, has elected attorney Jason W. Schigelone as counsel, effective January 2015. Mr. Schigelone specializes in patent prosecution and ...
May 8, 2013
On May 8, Jason W. Schigelone will be speaking in the panel "Examining New Rulings in Inducement of Infringement and Divided Infringement and Their Application to Method Claims in Hatch-Waxman Litigation" at ACI's Paragraph VI ...
Affiliations
  • American Bar Association
    Intellectual Property Section
  • Intellectual Property Owners Association
Back to Top